Press Releases for MNTA

Press Releases
Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of Three COPAXONE®-Related Patents
Teva Comments on Mylan Paragraph IV Filing for COPAXONE®; Files Lawsuit Against Generic Filer for Patent Infringement
Momenta Pharmaceuticals, Inc. Announces Closing of Offering and Exercise of Over-Allotment Option
U.S. drug approval head conflict probed
Momenta Pharmaceuticals Reports Financial Results for the Second Quarter of 2009
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Second Quarter 2009 Financial Results
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
Momenta Pharmaceuticals Announces Appointment of Bruce L. Downey to Board of Directors
Momenta Pharmaceuticals to Present At the Goldman Sachs 30th Annual Global Healthcare Conference
Momenta Pharmaceuticals to Present At the Deutsche Bank 34th Annual Health Care Conference
Momenta Pharmaceuticals to Present At the Deutsche Bank 34th Annual Health Care Conference
Momenta Pharmaceuticals Reports Financial Results for the First Quarter of 2009
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for First Quarter 2009 Financial Results
Momenta Pharmaceuticals Presents Preclinical Data for Novel Oncology Compound M402 at AACR Meeting
Momenta Pharmaceuticals to Present M402 Preclinical Data At Upcoming AACR Meeting
Momenta Pharmaceuticals to Present At Cowen and Company 29th Annual Health Care Conference
Momenta Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year End 2008
Momenta Pharmaceuticals to Present At the 11th Annual BIO CEO & Investor Conference
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Fourth Quarter and Year Ended 2008 Financial Results
Momenta Pharmaceuticals to Present At The 27th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals to Raise $24.1 Million Through Registered Direct Offering
Momenta Pharmaceuticals Announces Appointment of James R. Sulat as Chairman of the Board of Directors
Momenta Pharmaceuticals to Present At Upcoming Conferences
Momenta Pharmaceuticals Reports Financial Results for the Third Quarter of 2008
Momenta Pharmaceuticals to Present At Oppenheimer 19th Annual Healthcare Conference
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Third Quarter 2008 Financial Results
Momenta Pharmaceuticals to Present At the UBS Global Life Science Conference
Momenta Pharmaceuticals to Present At the 3rd Annual Citi Biotech Day
Momenta Pharmaceuticals to Present At the Morgan Stanley Global Healthcare Unplugged Conference
Momenta Pharmaceuticals Announces Results From a Phase 1 Study of M118 Administered as a Subcutaneous Injection
Momenta Pharmaceuticals Announces Results from M118 Drug-Drug Interaction Study with Aspirin and Clopidogrel
Momenta Pharmaceuticals Announces Data Presentations On M118 At Upcoming IXth World Conference On Clinical Pharmacology and Therapeutics Meeting
Momenta Pharmaceuticals Reports Financial Results for the Second Quarter of 2008
Momenta Pharmaceuticals Appoints Bruce A. Leicher as General Counsel
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Second Quarter 2008 Financial Results
BeaconEquity.com Issues TraderNotes on Active Stocks: SPSN, CHCG, DTPI, AMKR, TQNT, MNTA, CBPC, ABAT
Momenta Pharmaceuticals Announces Filing of Abbreviated New Drug Application With a Paragraph IV Certification for Generic Version of Copaxone
Momenta Pharmaceuticals Announces Appointment of James R. Sulat to Board of Directors
Momenta Pharmaceuticals to Present At the Seventh Annual Needham Biotechnology & Medical Technology Conference
Momenta Pharmaceuticals to Present At 2008 Citi Investment Research Global Healthcare Conference
Momenta Pharmaceuticals Announces Date for 2008 Annual Meeting of Stockholders
Momenta Pharmaceuticals Reports Financial Results for the First Quarter of 2008
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for First Quarter 2008 Financial Results
Momenta Pharmaceuticals Receives Regulatory Guidance On M-Enoxaparin ANDA
Momenta Pharmaceuticals to Present At Deutsche Bank 33rd Annual Health Care Conference
Momenta Pharmaceuticals to Present At 2008 Morgan Stanley Global Healthcare Unplugged Conference
Momenta Pharmaceuticals Announces Presentation of M118 Phase 1 Results At the American Society for Clinical Pharmacology and Therapeutics Annual Meeting